Syngene International Limited , a leading contract research organization, has reported strong financial results for the first quarter. The company's performance demonstrates robust growth and improved profitability.

Financial Highlights

• Revenue from operations increased by 11% year-on-year to Rs. 875.00 crores
• Reported EBITDA grew by 19% to Rs. 224.00 crores
• EBITDA margin improved to 25% from 23% in the same quarter last year
• Reported Profit After Tax (PAT) surged by 59% to Rs. 87.00 crores

Revenue and Profitability

Syngene's revenue from operations for the quarter stood at Rs. 875.00 crores, marking an 11% increase from Rs. 790.00 crores in the corresponding quarter of the previous year. This growth was primarily driven by the continued conversion of pilot programs into longer-term contracts within the company's Research Services business.

The company's reported EBITDA saw a significant rise of 19%, reaching Rs. 224.00 crores. The EBITDA margin also improved, increasing from 23% to 25%, reflecting enhanced operational efficiency and cost management.

Profit After Tax (PAT) showed remarkable growth, increasing by 59% to Rs. 87.00 crores compared to Rs. 54.00 crores in the same quarter of the previous year. The substantial increase in PAT can be attributed to revenue growth, improved operational performance, and a focus on cost optimization.

Operational Highlights

Syngene made notable progress in various operational areas during the quarter:

1. Successfully completed a USFDA Good Clinical Practices inspection with no observations.
2. Inaugurated a new peptide laboratory, expanding its scientific platform capabilities.
3. Started operations at its Unit III facility in Bengaluru.
4. Advanced preparations to commence operations at the Bayview facility in the U.S. later this year.

Management Commentary

Peter Bains, Managing Director and CEO of Syngene International Limited, commented on the results: "We are pleased with the growth performance in the first quarter, which is aligned with our expectations. Continued conversion of pilot programs into longer-term contracts within our Research Services business was the main driver underpinning this momentum."

Deepak Jain, Chief Financial Officer, added: "Operating EBITDA margins came at around 24%, driven by both revenue growth and a focus on cost optimization. The current quarter's PAT includes a tax benefit arising from transfer of gratuity funds to Employee Gratuity Trust."

Recognition and Sustainability

Syngene was recognized by TIME magazine and Statista as one of the World's Most Sustainable Companies. The company ranked #1 in India among companies in the pharma and biotech sectors and was placed in the top 20 life science companies globally.

Key Management Personnel Update

The company has updated its list of Key Managerial Personnel authorized to determine materiality of events:

1. Peter Bains - Managing Director and CEO
2. Deepak Jain - Chief Financial Officer
3. Chethan Yogesh - Company Secretary and Compliance Officer

Outlook

While remaining mindful of ongoing macroeconomic factors, Syngene's management maintains a confident outlook for the future. The company continues to invest in technology and capabilities to strengthen its customer offerings and remains on course to deliver in line with its stated guidance for the year.

Syngene International Limited's strong start to the fiscal year demonstrates its resilience and ability to grow in a challenging global environment. The company's focus on expanding its capabilities, improving operational efficiency, and maintaining a strong financial position bodes well for its future prospects in the contract research and manufacturing services sector.

Syngene International , a leading contract research organization, has reported a strong start to the fiscal year 2026, with revenue from operations growing by 11% year-on-year to Rs. 875.00 crore in the first quarter. The company's financial results, released on July 23, 2025, showcase resilience and continued momentum in its business operations.

Financial Highlights

• Revenue from operations increased to Rs. 875.00 crore, up from Rs. 790.00 crore in Q1 FY25
• Reported EBITDA rose by 19% year-on-year to Rs. 224.00 crore
• EBITDA margin improved to 25%, compared to 23% in the same quarter last year
• Profit After Tax (PAT) before exceptional items surged by 59% to Rs. 87.00 crore

Operational Highlights

Syngene's performance was driven by continued conversion of pilot programs into longer-term contracts within its Research Services business. The company also made progress in its Biologics manufacturing division, with the start of operations at the Unit III facility in Bengaluru and advancing preparations for the Bayview facility in the U.S.

Peter Bains, Managing Director and CEO of Syngene International, commented on the results, stating, "We are pleased with the growth performance in the first quarter, which is aligned with our expectations. While we remain mindful of ongoing macroeconomic factors, we maintain a confident outlook."

Strategic Developments

The company has strengthened its scientific capabilities by inaugurating a state-of-the-art, dedicated peptide laboratory. This addition complements Syngene's existing expertise in monoclonal antibodies, Antibody-Drug Conjugates, Oligonucleotides, and PROTACs.

Regulatory Compliance and Quality Assurance

Syngene successfully completed a USFDA Good Clinical Practices (GCP) inspection of its Human Pharmacology Unit with no observations. The company's Biologics facility at Biocon Park received an Establishment Inspection Report (EIR) with a favorable Voluntary Action Indicated (VAI) outcome. Additionally, Syngene concluded over 20 client and regulatory audits in Q1 FY26, reinforcing its commitment to global quality and integrity standards.

Sustainability Recognition

Syngene was recognized by TIME magazine and Statista as one of the World's Most Sustainable Companies in 2025. The company ranked #1 in India among companies in the pharma and biotech sectors and was placed in the top 20 life science companies globally.

Outlook

Deepak Jain, Chief Financial Officer of Syngene International, expressed satisfaction with the company's financial performance and stated, "We continue to maintain a robust balance sheet enabling us to invest in technology and capabilities to strengthen our customer offerings. While keeping a close watch on market trends, we remain on course to deliver in line with our stated guidance for the year."

As Syngene International continues to navigate the evolving economic landscape, the company's strong start to FY26 and its reaffirmation of annual guidance demonstrate its resilience and strategic focus on long-term growth in the contract research and manufacturing services sector.